KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Capital Expenditures (2016 - 2024)

Historic Capital Expenditures for Rigel Pharmaceuticals (RIGL) over the last 15 years, with Q4 2024 value amounting to $26000.0.

  • Rigel Pharmaceuticals' Capital Expenditures changed N/A to $26000.0 in Q4 2024 from the same period last year, while for Dec 2024 it was $252000.0, marking a year-over-year change of. This contributed to the annual value of $36000.0 for FY2024, which is N/A changed from last year.
  • Latest data reveals that Rigel Pharmaceuticals reported Capital Expenditures of $26000.0 as of Q4 2024.
  • Over the past 5 years, Rigel Pharmaceuticals' Capital Expenditures peaked at $607000.0 during Q1 2020, and registered a low of -$44000.0 during Q2 2020.
  • Moreover, its 4-year median value for Capital Expenditures was $170000.0 (2021), whereas its average is $181923.1.
  • As far as peak fluctuations go, Rigel Pharmaceuticals' Capital Expenditures tumbled by 13826.09% in 2020, and later surged by 102500.0% in 2021.
  • Over the past 4 years, Rigel Pharmaceuticals' Capital Expenditures (Quarter) stood at $504000.0 in 2020, then plummeted by 104.17% to -$21000.0 in 2021, then soared by 447.62% to $73000.0 in 2022, then crashed by 64.38% to $26000.0 in 2024.
  • Its Capital Expenditures stands at $26000.0 for Q4 2024, versus $73000.0 for Q4 2022 and $189000.0 for Q3 2022.